Last reviewed · How we verify
Placebo to indacaterol — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo to indacaterol (Placebo to indacaterol) — Novartis. Placebo has no active pharmacological mechanism and serves as a control comparator in clinical trials.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo to indacaterol TARGET | Placebo to indacaterol | Novartis | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo to indacaterol CI watch — RSS
- Placebo to indacaterol CI watch — Atom
- Placebo to indacaterol CI watch — JSON
- Placebo to indacaterol alone — RSS
Cite this brief
Drug Landscape (2026). Placebo to indacaterol — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-indacaterol. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab